Evaluation of the Sensitivity and Specificity of a Novel Quality of Life Tool to Assess the Treatment Satisfaction in Psoriasis Patients

Overview

The severity of psoriasis can be influenced by a great variety of factors including extent of the disease, lesions location and impact on quality of life. The current standard of care for psoriasis is focusing on the reduction of the skin symptoms as defined by the PASI, somewhat setting asides the patient's feelings in terms of which aspects of his/her life are affected by the disease. Despite the fact that multiple patient reported outcomes (PRO) questionnaires are available to evaluate the impact of the disease on patients' quality of life, only few items address the subjective impact of skin disease. Among the available PROs the Dermatology Life Quality Index (DLQI) is the most frequently used. It is a standardized tool designed to cover a broad range of dermatologic afflictions but lacks specificity towards the effect of psoriasis on quality of life. The DLQI is composed of ten questions grouped in 6 domains "symptoms and feelings", "daily activities", "leisure", "work/school", "personal relationships" and "treatment". Each answer is graded from 0 to 3. The DLQI score is calculated by adding the score of each question, resulting in a maximum score of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. A score higher than 10 indicates that the patient's life is being severely affected by their skin disease. Because of its limitations, some patients cannot seem to completely restore a normal quality of life (e.g. DLQI 0-1) even though their reached a perfect PASI score (100). This phenomenon may be explained by the fact that the patient's own perception can be different from the physician's perspective and may have changed in time, between follow-ups. These are as many reasons as why it is highly difficult to accurately fathom the therapeutic expectations of the psoriasis patients. The standard tools currently in use are not able to assess the perception of the disease by the patient its evolution over time. In addition, it is widely recognized that alexithymia is more prevalent in the psoriasis patients than in the general population and patients with alexithymia appear to suffer higher psoriasis burden as they have more difficulties to express their expectations. Since patients struggle to recognize and verbalize their emotions, it can be useful and informative to offer patients a variety of verbatim in which they can identify. PSO-TARGET is an exploratory observational, non-interventional study aiming to evaluate a novel approach of assessing psoriasis patients' satisfaction towards their biologic treatment from a quality of life standpoint by using a psoriasis-specific Quality of Life assessment grid. The aim of this exploratory study is to evaluate the sensitivity and specificity of the PSO-TARGET QoL Component grid as part of a new approach for assessing the level of achievement of the psoriasis patient's therapeutic goal, identified by himself, after a treatment with Kyntheum®.

Full Title of Study: “Evaluation of the Sensitivity and Specificity of a Novel Quality of Life (QoL) Tool to Assess the Treatment Satisfaction in Psoriasis Patients”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 30, 2022

Interventions

  • Other: DLQI and PSO-TARGET QoL grid
    • At inclusion visit, and after 3 and 12 months, the patient will fill a patient questionnaire containing DLQI and PSO-TARGET QoL grid

Arms, Groups and Cohorts

  • Included patients
    • Fill patient questionnaires at inclusion visit, around 3 months and 12 months

Clinical Trial Outcome Measures

Primary Measures

  • Level of concordance between the satisfaction level in regard to the therapeutic objective set by the PSO-TARGET QoL Component grid and the DLQI in assessing the impact of the treatment on the patients’ quality of life.
    • Time Frame: At first follow-up visit (around 12 weeks)

Secondary Measures

  • The percentage of patients who achieved the main treatment goal identified by the patient himself in the QoL component grid at baseline.
    • Time Frame: At first follow-up visit (around 12 weeks)
    • The therapeutic objective achievement is defined as “satisfied” or “very satisfied” response on 4 points Likert scale.
  • Level of concordance between the satisfaction level in regard to the therapeutic objective set by the PSO-TARGET QoL Component grid and the DLQI
    • Time Frame: At last follow up (around 52 weeks)
  • Research of predictive factors (among baseline characteristics) of the achievement of the main treatment goal.
    • Time Frame: At first follow-up visit (around 12 weeks)
  • Percentage of agreement between the physician-reported and the patient-reported dimensions
    • Time Frame: At first follow-up visit (around 12 weeks)
  • Rate of patients having changed objective at the 1st follow-up visit
    • Time Frame: At first follow-up visit (around 12 weeks)
  • Percentage of patients who have maintained at 52 ± 4 weeks the level of satisfaction achieved at the 1st follow-up visit.
    • Time Frame: At last follow up (around 52 weeks)
  • Psoriasis Area and Severity Index (PASI)
    • Time Frame: at baseline
    • Calculation of the percentage of skin surface area affected. Estimation of how many hands surface (palm + fingers) of the patient correspond to psoriatic lesions. one hand surface is considered as 1% of total body skin surface
  • Psoriasis Area and Severity Index (PASI)
    • Time Frame: at the 1st follow-up visit ), at the 2nd follow-up visit (52 ± 4 weeks.).
    • Calculation of the percentage of skin surface area affected. Estimation of how many hands surface (palm + fingers) of the patient correspond to psoriatic lesions. one hand surface is considered as 1% of total body skin surface
  • Psoriasis Area and Severity Index (PASI)
    • Time Frame: at the 2nd follow-up visit (around 52 weeks.).
    • Calculation of the percentage of skin surface area affected. Estimation of how many hands surface (palm + fingers) of the patient correspond to psoriatic lesions. one hand surface is considered as 1% of total body skin surface
  • Level of accordance between PASI 90/100 and the satisfaction level in regard to the therapeutic objective set by the PSO-TARGET QoL Component grid.
    • Time Frame: at baseline, at the 1st follow-up visit (12/ 16 weeks), at the 2nd follow-up visit 52 ± 4 weeks.
  • Level of accordance between PASI 90/100 and the satisfaction level in regard to the therapeutic objective set by the PSO-TARGET QoL Component grid.
    • Time Frame: at the 1st follow-up visit (around 12 weeks)
  • Level of accordance between PASI 90/100 and the satisfaction level in regard to the therapeutic objective set by the PSO-TARGET QoL Component grid.
    • Time Frame: at the 2nd follow-up visit (around 52 weeks)
  • Dermatology Life Quality Index (DLQI Scores)
    • Time Frame: at baseline
    • Patient questionnaire, score is calculated between 0 (worst score possible) and 30 (best score possible)
  • Dermatology Life Quality Index (DLQI Scores)
    • Time Frame: at the 1st follow-up visit (around 12 weeks)
    • Patient questionnaire, score is calculated between 0 (worst score possible) and 30 (best score possible)
  • Dermatology Life Quality Index (DLQI Scores)
    • Time Frame: at the 2nd follow-up visit (around 52 weeks)
    • Patient questionnaire, score is calculated between 0 (worst score possible) and 30 (best score possible)

Participating in This Clinical Trial

Inclusion Criteria

  • Age > 18 years – Patient for whom the dermatologist decided to initiate a treatment by Kyntheum® according to SmPC. – Patient who signed an informed consent Exclusion Criteria:

  • Vulnerable subjects according to the law; – pregnant, parturient or breast feeding women; – deprived of their freedom by administrative, medical or legal decision or who is under trusteeship/guardianship; – legally protected, or unable to express their consent to participate; – With no affiliation to a social security system; – Psychologically/linguistically unable to express their consent to participate – With an hypersensitivity to at least one of the excipients of Kyntheum® – Participating at the same time in another clinical trial

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Clinact
  • Collaborator
    • LEO Pharma
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Ziad Reguiai, Dr. MED, Principal Investigator, POLYCLINIQUE DE COURLANCY-BEZANES
  • Overall Contact(s)
    • Kelly Tiercelet, +33180131470, kelly.tiercelet@clinact.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.